# The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters

> **NCT07173127** · NA · RECRUITING · sponsor: **University Hospital, Geneva** · enrollment: 30 (estimated)

## Conditions studied

- Uterine Fibroid

## Interventions

- **DRUG:** Ryeqo treatment

## Key facts

- **NCT ID:** NCT07173127
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07173127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07173127, "The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07173127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*